Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pulmonology · Genetic Interstitial Lung Disease

Long-Term Disease Management and Monitoring

At a Glance

Living with genetic interstitial lung disease (ILD) requires lifelong management. Care focuses on stabilizing lung function and maintaining quality of life through regular pulmonary function tests (PFTs), periodic CT scans, supplemental oxygen, and pulmonary rehabilitation.

Living with a genetic interstitial lung disease (ILD) is a marathon, not a sprint. Because conditions like SFTPC-related ILD (ILD2) or ABCA3 deficiency are chronic and progressive, the focus shifts from a “cure” to a strategy of stability and quality of life [1][2]. Understanding how your medical team monitors the disease can help you feel more in control of the journey and prepare for what to expect over the long term.

Factors Affecting Your Outlook

While the term “prognosis” can be scary, it is important to remember that genetic ILDs are highly variable. Two people with the exact same mutation can have very different experiences [1].

  • The Specific Mutation: Some mutations in ABCA3 or SFTPC are known to be more aggressive, while others may allow for long-term stability with minimal intervention [3][4].
  • Age of Onset: Generally, infants who survive the initial newborn period often show a capacity for the lungs to grow and compensate, though they may have lifelong reduced capacity [5][6]. Adult-onset cases typically follow a slower, more progressive path toward fibrosis (scarring) [7].
  • Response to Therapy: Patients who respond well to initial stabilization (like hydroxychloroquine) often have a more predictable course [8][9].

Monitoring Your Progress

Your care team will use a combination of “snapshots” (imaging) and “functional tests” (breathing) to track the disease.

1. Pulmonary Function Tests (PFTs)

These are the most common tools for tracking stability:

  • Forced Vital Capacity (FVC): This measures the total amount of air you can exhale. A drop of 5-10% over 6 to 12 months is often used as a signal that the disease may be progressing [10][11].
  • DLCO (Diffusing Capacity): This measures how well oxygen moves from the lungs into the blood. In genetic ILD, a lower DLCO often indicates that the air sac walls are thickening or scarring [12][10].

2. Imaging (HRCT)

High-resolution CT (HRCT) scans provide the most detail but involve radiation. For stable patients, scans may only happen every 12 to 24 months [13]. Doctors look for “ground-glass” haziness (inflammation) or “reticulation” (the beginning of scarring) [7][13].

3. Blood Biomarkers

Specialized tests for markers like KL-6 and SP-D can act like a “thermometer” for the lungs. Rising levels of these markers often correlate with active damage to the lung’s alveolar type 2 cells [14][15]. Note that while these tests are standard in some countries (like Japan), they may only be available at specialized research centers in the US or Europe.

General Surveillance Schedule

While every plan is highly individualized based on disease severity and standard practices at your care center, a general monitoring schedule often looks like this:

Frequency Test / Evaluation Purpose
Every 3-6 Months PFTs & 6-Minute Walk Test Tracking lung volume and oxygen levels during activity [10].
Every 1-2 Years HRCT Scan Checking for physical changes in lung structure [13].
As Needed Echocardiogram Checking for pulmonary hypertension (high pressure in lung arteries) [16].

Managing Quality of Life

Living with chronic lung disease can bring significant symptom burdens like cough and shortness of breath [17].

  • Supplemental Oxygen: Using oxygen during exercise can improve quality of life and allow you to stay active [18][19].
  • Pulmonary Rehabilitation: This specialized exercise program is one of the most effective ways to improve your “functional capacity” and help you breathe more efficiently [20][21].
  • Scan Anxiety: It is normal to feel “scanxiety” before a CT. Using tools like the K-BILD questionnaire can help you and your doctor talk about the impact of the disease on your life, not just the pictures on the screen [22][23].

Though genetic ILD is a lifelong condition, many patients maintain meaningful quality of life for decades with appropriate supportive care, monitoring, and, when necessary, advanced options like lung transplantation [24][4].

Common questions in this guide

How do doctors monitor genetic interstitial lung disease?
Doctors track genetic ILD using a combination of pulmonary function tests (PFTs) to measure breathing capacity and high-resolution CT scans to check for lung scarring. At specialized centers, they may also use blood biomarkers to monitor lung cell stress.
How often will I need tests and scans for ILD?
A typical surveillance schedule includes breathing tests and a 6-minute walk test every 3 to 6 months, along with a CT scan every 1 to 2 years. Your exact schedule will be customized based on your disease severity and your care center's practices.
How does my specific genetic mutation affect my ILD prognosis?
Different genetic mutations behave differently. Some ABCA3 or SFTPC mutations allow for long-term stability with minimal treatment, while others may cause faster progression toward lung scarring. Your age of onset also plays a role in your long-term outlook.
What are KL-6 and SP-D tests used for in ILD?
KL-6 and SP-D are specialized blood biomarkers that act like a thermometer for the lungs. Rising levels of these markers often indicate active damage or inflammation in the lung cells, helping doctors track disease activity.
Will pulmonary rehabilitation help with my genetic ILD?
Yes, pulmonary rehabilitation is highly recommended. It is a specialized exercise and education program designed to improve your functional capacity, help you breathe more efficiently, and enhance your overall quality of life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my (or my child's) current FVC percentage, and how has it changed since our last visit?
  2. 2.Given this specific mutation, what are the most important 'red flags' we should watch for that might signal a flare or progression?
  3. 3.Can we measure biomarkers like KL-6 or SP-D to help track the level of stress on the lung cells?
  4. 4.When should we schedule our next HRCT, and how are you balancing the need for imaging with concerns about radiation exposure?
  5. 5.Is pulmonary rehabilitation available to help improve physical stamina and quality of life?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    THERAPIES FOR NEONATAL DISEASES OF THE SURFACTANT SYSTEM.

    McCray PB

    Transactions of the American Clinical and Climatological Association 2025; (135()):119-129.

    PMID: 40771632
  2. 2

    Surfactant protein disorders in childhood interstitial lung disease.

    Singh J, Jaffe A, Schultz A, Selvadurai H

    European journal of pediatrics 2021; (180(9)):2711-2721 doi:10.1007/s00431-021-04066-3.

    PMID: 33839914
  3. 3

    Hydroxychloroquine, a successful treatment for lung disease in ABCA3 deficiency gene mutation: a case report.

    Shaaban W, Hammoud M, Abdulraheem A, et al.

    Journal of medical case reports 2021; (15(1)):54 doi:10.1186/s13256-020-02604-5.

    PMID: 33526094
  4. 4

    Surfactant Protein C Deficiency in a Puerto Rican Adolescent With a Rare SFTPC Genetic Variant.

    Acosta-Rivera V, Melendez-Montañez JM, Diaz-Sotomayor F, De Jesús-Rojas W

    Cureus 2021; (13(8)):e17422 doi:10.7759/cureus.17422.

    PMID: 34589332
  5. 5

    Chronic ventilation in infants with surfactant protein C mutations: an alternative to lung transplantation.

    Liptzin DR, Patel T, Deterding RR

    American journal of respiratory and critical care medicine 2015; (191(11)):1338-40 doi:10.1164/rccm.201411-1955LE.

    PMID: 26029841
  6. 6

    Childhood interstitial lung disease survivors in adulthood: a European collaborative study.

    Manali ED, Griese M, Nathan N, et al.

    The European respiratory journal 2025; (65(2)) doi:10.1183/13993003.00680-2024.

    PMID: 39638417
  7. 7

    A rare interstitial lung disease in young adulthood due to surfactant protein C gene mutation: Two case reports with brief literature review.

    Sengul Y, Gosche E, Hazelton T

    Radiology case reports 2025; (20(9)):4299-4303 doi:10.1016/j.radcr.2025.05.051.

    PMID: 40575365
  8. 8

    Congenital Surfactant C Deficiency with Pulmonary Hypertension-A Case Report.

    Chua WC, Chen IC, Liu YC, et al.

    Children (Basel, Switzerland) 2022; (9(10)) doi:10.3390/children9101435.

    PMID: 36291368
  9. 9

    Surfactant protein C dysfunction with new clinical insights for diffuse alveolar hemorrhage and autoimmunity.

    Tang X, Shen Y, Zhou C, et al.

    Pediatric investigation 2019; (3(4)):201-206 doi:10.1002/ped4.12162.

    PMID: 32851322
  10. 10

    Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review.

    Hoffmann-Vold AM, Maher TM, Philpot EE, et al.

    ERJ open research 2021; (7(1)) doi:10.1183/23120541.00235-2020.

    PMID: 33644224
  11. 11

    Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

    Flaherty KR, Wells AU, Cottin V, et al.

    The New England journal of medicine 2019; (381(18)):1718-1727 doi:10.1056/NEJMoa1908681.

    PMID: 31566307
  12. 12

    Understanding Pulmonary Fibrosis in Pediatric Interstitial Lung Disease: A Comprehensive Analysis.

    Kekec H, Aslan AT, Akdulum I, et al.

    Chest 2026; doi:10.1016/j.chest.2026.01.022.

    PMID: 41740922
  13. 13

    Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.

    Carnevale A, Silva M, Maietti E, et al.

    Clinical rheumatology 2021; (40(1)):213-219 doi:10.1007/s10067-020-05375-y.

    PMID: 32880053
  14. 14

    Diagnostic performance of specific biomarkers for interstitial lung disease: a single center study.

    Maharjan AS, Amjadi SS, Jaskowski TD, et al.

    Clinical chemistry and laboratory medicine 2025; (63(4)):797-804 doi:10.1515/cclm-2024-1048.

    PMID: 39608015
  15. 15

    Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.

    Yamakawa H, Hagiwara E, Ikeda S, et al.

    Respiratory investigation 2019; (57(5)):422-429 doi:10.1016/j.resinv.2019.03.006.

    PMID: 31003951
  16. 16

    Case Report: Hydroxychloroquine in an infant with NKX2-1-associated interstitial lung disease.

    Qing D, Xu X, Shi T, et al.

    Frontiers in pediatrics 2025; (13()):1619722 doi:10.3389/fped.2025.1619722.

    PMID: 41181172
  17. 17

    Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review.

    Carvajalino S, Reigada C, Johnson MJ, et al.

    BMC pulmonary medicine 2018; (18(1)):78 doi:10.1186/s12890-018-0651-3.

    PMID: 29788938
  18. 18

    Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

    Visca D, Mori L, Tsipouri V, et al.

    The Lancet. Respiratory medicine 2018; (6(10)):759-770 doi:10.1016/S2213-2600(18)30289-3.

    PMID: 30170904
  19. 19

    A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.

    King CS, Flaherty KR, Glassberg MK, et al.

    Annals of the American Thoracic Society 2022; (19(4)):594-602 doi:10.1513/AnnalsATS.202107-864OC.

    PMID: 34678128
  20. 20

    Effectiveness of Pulmonary Rehabilitation in Interstitial Lung Disease, Including Coronavirus Diseases: A Systematic Review and Meta-analysis.

    Reina-Gutiérrez S, Torres-Costoso A, Martínez-Vizcaíno V, et al.

    Archives of physical medicine and rehabilitation 2021; (102(10)):1989-1997.e3 doi:10.1016/j.apmr.2021.03.035.

    PMID: 33932361
  21. 21

    Exercise Rehabilitation and Chronic Respiratory Diseases: Effects, Mechanisms, and Therapeutic Benefits.

    Xiong T, Bai X, Wei X, et al.

    International journal of chronic obstructive pulmonary disease 2023; (18()):1251-1266 doi:10.2147/COPD.S408325.

    PMID: 37362621
  22. 22

    The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.

    Birring SS, Bushnell DM, Baldwin M, et al.

    The European respiratory journal 2022; (59(6)) doi:10.1183/13993003.01790-2021.

    PMID: 34764181
  23. 23

    King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference.

    Nolan CM, Birring SS, Maddocks M, et al.

    The European respiratory journal 2019; (54(3)) doi:10.1183/13993003.00281-2019.

    PMID: 31221807
  24. 24

    Outcome of lung transplantation for adults with interstitial lung disease associated with genetic disorders of the surfactant system.

    Bermudez J, Nathan N, Coiffard B, et al.

    ERJ open research 2023; (9(6)) doi:10.1183/23120541.00240-2023.

    PMID: 38020562

This page explains long-term management for genetic interstitial lung disease for educational purposes only. Always consult your pulmonologist to determine the best monitoring schedule and care plan for your specific condition.

Get notified when new evidence is published on Interstitial lung disease 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.